Search

Your search keyword '"Regina Ercole"' showing total 9 results
Start Over Author "Regina Ercole"
9 results on '"Regina Ercole"'

1. The Lambda Variant in Argentina: Analyzing the Evolution and Spread of SARS-CoV-2 Lineage C.37

Author

Mercedes Soledad Nabaes Jodar, Carolina Torres, Laura Mojsiejczuk, Dolores Acuña, Laura Elena Valinotto, Stephanie Goya, Monica Natale, Silvina Lusso, Sofia Alexay, Ariel Amadio, Matias Irazoqui, Franco Fernandez, Maria Elina Acevedo, Cristina Alvarez Lopez, Andres Angelletti, Paula Aulicino, Elisa Bolatti, Bettina Brusés, Marco Cacciahue, Ana Cavatorta, Agustina Cerri, Andres Cordero, Humberto Debat, Maria Jose Dus Santos, Maria Florencia Eberhardt, Regina Ercole, Carlos Espul, Marisa Farber, Fabián Fay, Ailen Fernandez, Florencia Ferrini, Laura Formichelli, Santiago Ceballos, Fernando Gallego, Adriana Giri, Maria Gismondi, Raul Maximiliano Acevedo, Ivan Gramundi, María Eugenia Ibañez, Guido Konig, Viviana Leiva, Melina Lorenzini Campos, Horacio Lucero, Nathalie Marquez, Melina Mazzeo, Alicia Susana Mistchenko, Luciana Montoto, Marianne Muñoz, Victoria Nadalich, Cristina Nardi, Belén Ortiz, Luis Pianciola, Carolina Pintos, Andrea Puebla, Carolina Rastellini, Alejandro Ezequiel Rojas, Javier Sfalcin, Ariel Suarez, Clara Theaux, Guillermo Thomas, Estefania Tittarelli, Rosana Toro, Vanina Villanova, Gretel Wenk, Cecilia Ziehm, Maria Carla Zimmermann, Sebastian Zunino, Proyecto PAIS, and Mariana Viegas

Subjects
SARS-CoV-2, Lambda, variants, evolution, South America, phylodynamic, Microbiology, QR1-502
Abstract

The second wave of COVID-19 occurred in South America in early 2021 and was mainly driven by Gamma and Lambda variants. In this study, we aimed to describe the emergence and local genomic diversity of the SARS-CoV-2 Lambda variant in Argentina, from its initial entry into the country until its detection ceased. Molecular surveillance was conducted on 9356 samples from Argentina between October 2020 and April 2022, and sequencing, phylogenetic, and phylogeographic analyses were performed. Our findings revealed that the Lambda variant was first detected in Argentina in January 2021 and steadily increased in frequency until it peaked in April 2021, with continued detection throughout the year. Phylodynamic analyses showed that at least 18 introductions of the Lambda variant into the country occurred, with nine of them having evidence of onward local transmission. The spatial–-temporal reconstruction showed that Argentine clades were associated with Lambda sequences from Latin America and suggested an initial diversification in the Metropolitan Area of Buenos Aires before spreading to other regions in Argentina. Genetic analyses of genome sequences allowed us to describe the mutational patterns of the Argentine Lambda sequences and detect the emergence of rare mutations in an immunocompromised patient. Our study highlights the importance of genomic surveillance in identifying the introduction and geographical distribution of the SARS-CoV-2 Lambda variant, as well as in monitoring the emergence of mutations that could be involved in the evolutionary leaps that characterize variants of concern.

Published
2023
Full Text
View/download PDF

2. Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time

Author

María M. Gonzalez Lopez Ledesma, Lautaro Sanchez, Diego S. Ojeda, Santiago Oviedo Rouco, Andrés H. Rossi, Augusto Varese, Ignacio Mazzitelli, Carla A. Pascuale, Esteban A. Miglietta, Pamela E. Rodríguez, Horacio M. Pallarés, Guadalupe S. Costa Navarro, Julio J. Caramelo, Paul W. Rothlauf, Zhuoming Liu, Louis-Marie Bloyet, Marjorie Cornejo Pontelli, Natali B. Rasetto, Shirley D. Wenker, Lila Y. Ramis, Magalí G. Bialer, María Jose de Leone, C. Esteban Hernando, Luciana Bianchimano, Antonella S. Ríos, María Soledad Treffinger Cienfuegos, Diana R. Rodriguez García, Yesica Longueira, Natalia Laufer, Diego Alvarez, Ana Ceballos, Valeria Ochoa, Cecilia Monzani, Gariela Turk, Melina Salvatori, Jorge Carradori, Katherine Prost, Alejandra Rima, Claudia Varela, Regina Ercole, Rosana I. Toro, Sebastian Gutierrez, Martín Zubieta, Dolores Acuña, Mercedes S. Nabaes Jodar, Carolina Torres, Laura Mojsiejczuk, Mariana Viegas, Pilar Velazquez, Clarisa Testa, Nicolas Kreplak, Marcelo Yanovsky, Sean Whelan, Jorge Geffner, Marina Pifano, and Andrea V. Gamarnik

Subjects
COVID-19, SARS CoV-2, Sputnik V, viral variants, Microbiology, QR1-502
Abstract

ABSTRACT Recent studies have shown a temporal increase in the neutralizing antibody potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent individuals. Here, we examined longitudinal antibody responses and viral neutralizing capacity to the B.1 lineage virus (Wuhan related), to variants of concern (VOC; Alpha, Beta, Gamma, and Delta), and to a local variant of interest (VOI; Lambda) in volunteers receiving the Sputnik V vaccine in Argentina. Longitudinal serum samples (N = 536) collected from 118 volunteers obtained between January and October 2021 were used. The analysis indicates that while anti-spike IgG levels significantly wane over time, the neutralizing capacity for the Wuhan-related lineages of SARS-CoV-2 and VOC is maintained within 6 months of vaccination. In addition, an improved antibody cross-neutralizing ability for circulating variants of concern (Beta and Gamma) was observed over time postvaccination. The viral variants that displayed higher escape to neutralizing antibodies with respect to the original virus (Beta and Gamma variants) were the ones showing the largest increase in susceptibility to neutralization over time after vaccination. Our observations indicate that serum neutralizing antibodies are maintained for at least 6 months and show a reduction of VOC escape to neutralizing antibodies over time after vaccination. IMPORTANCE Vaccines have been produced in record time for SARS-CoV-2, offering the possibility of halting the global pandemic. However, inequalities in vaccine accessibility in different regions of the world create a need to increase international cooperation. Sputnik V is a recombinant adenovirus-based vaccine that has been widely used in Argentina and other developing countries, but limited information is available about its elicited immune responses. Here, we examined longitudinal antibody levels and viral neutralizing capacity elicited by Sputnik V vaccination. Using a cohort of 118 volunteers, we found that while anti-spike antibodies wane over time, the neutralizing capacity to viral variants of concern and local variants of interest is maintained within 4 months of vaccination. In addition, we observed an increased cross-neutralization activity over time for the Beta and Gamma variants. This study provides valuable information about the immune response generated by a vaccine platform used in many parts of the world.

Published
2022
Full Text
View/download PDF

3. Cost-Effective Method to Perform SARS-CoV-2 Variant Surveillance: Detection of Alpha, Gamma, Lambda, Delta, Epsilon, and Zeta in Argentina

Author

Carolina Torres, Laura Mojsiejczuk, Dolores Acuña, Sofía Alexay, Ariel Amadio, Paula Aulicino, Humberto Debat, Fabián Fay, Franco Fernández, Adriana A. Giri, Stephanie Goya, Guido König, Horacio Lucero, Mercedes Nabaes Jodar, Luis Pianciola, Javier A. Sfalcin, Raúl M. Acevedo, Sofía Bengoa Luoni, Elisa M. Bolatti, Bettina Brusés, Marco Cacciabue, Pablo E. Casal, Agustina Cerri, Diego Chouhy, María José Dus Santos, María Florencia Eberhardt, Ailen Fernandez, Paula del Carmen Fernández, Darío Fernández Do Porto, Laura Formichelli, María Inés Gismondi, Matías Irazoqui, Melina Lorenzini Campos, Silvina Lusso, Nathalie Marquez, Marianne Muñoz, Javier Mussin, Mónica Natale, Griselda Oria, María Belén Pisano, Victoria Posner, Andrea Puebla, Viviana Re, Ezequiel Sosa, Gabriela V. Villanova, Jonathan Zaiat, Sebastián Zunino, María Elina Acevedo, Julián Acosta, Cristina Alvarez Lopez, María Laura Álvarez, Patricia Angeleri, Andrés Angelletti, Manuel Arca, Natalia A. Ayala, Gabriela Barbas, Ana Bertone, Agustina Bonnet, Ignacio Bourlot, Victoria Cabassi, Alejandro Castello, Gonzalo Castro, Ana Laura Cavatorta, Carolina Ceriani, Carlos Cimmino, Julián Cipelli, María Colmeiro, Andrés Cordero, Carolina Cristina, Sofia Di Bella, Guillermina Dolcini, Regina Ercole, Yesica Espasandin, Carlos Espul, Andrea Falaschi, Facundo Fernandez Moll, María Delia Foussal, Andrea Gatelli, Sandra Goñi, María Estela Jofré, José Jaramillo, Natalia Labarta, María Agustina Lacaze, Rocio Larreche, Viviana Leiva, Gustavo Levin, Erica Luczak, Marcelo Mandile, Gioia Marino, Carla Massone, Melina Mazzeo, Carla Medina, Belén Monaco, Luciana Montoto, Viviana Mugna, Alejandra Musto, Victoria Nadalich, María Victoria Nieto, Guillermo Ojeda, Andrea C. Piedrabuena, Carolina Pintos, Marcia Pozzati, Marilina Rahhal, Claudia Rechimont, Federico Remes Lenicov, Gabriela Rompato, Vanesa Seery, Leticia Siri, Julieta Spina, Cintia Streitenberger, Ariel Suárez, Jorgelina Suárez, Paula Sujansky, Juan Manuel Talia, Clara Theaux, Guillermo Thomas, Marina Ticeira, Estefanía Tittarelli, Rosana Toro, Osvaldo Uez, María Belén Zaffanella, Cecilia Ziehm, and Martin Zubieta

Subjects
SARS-CoV-2, variants, South America, surveillance, spike sequences, Gamma, Medicine (General), R5-920
Abstract

SARS-CoV-2 variants with concerning characteristics have emerged since the end of 2020. Surveillance of SARS-CoV-2 variants was performed on a total of 4,851 samples from the capital city and 10 provinces of Argentina, during 51 epidemiological weeks (EWs) that covered the end of the first wave and the ongoing second wave of the COVID-19 pandemic in the country (EW 44/2020 to EW 41/2021). The surveillance strategy was mainly based on Sanger sequencing of a Spike coding region that allows the identification of signature mutations associated with variants. In addition, whole-genome sequences were obtained from 637 samples. The main variants found were Gamma and Lambda, and to a lesser extent, Alpha, Zeta, and Epsilon, and more recently, Delta. Whereas, Gamma dominated in different regions of the country, both Gamma and Lambda prevailed in the most populated area, the metropolitan region of Buenos Aires. The lineages that circulated on the first wave were replaced by emergent variants in a term of a few weeks. At the end of the ongoing second wave, Delta began to be detected, replacing Gamma and Lambda. This scenario is consistent with the Latin American variant landscape, so far characterized by a concurrent increase in Delta circulation and a stabilization in the number of cases. The cost-effective surveillance protocol presented here allowed for a rapid response in a resource-limited setting, added information on the expansion of Lambda in South America, and contributed to the implementation of public health measures to control the disease spread in Argentina.

Published
2021
Full Text
View/download PDF

4. Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273

Author

Carla A. Pascuale, Augusto Varese, Diego S. Ojeda, Marina E. Pasinovich, Laura Lopez, Andres H. Rossi, Pamela E. Rodriguez, Esteban A. Miglietta, Ignacio Mazzitelli, Facundo Di Diego Garcia, Lautaro Sanchez, Santiago Oviedo Rouco, María Mora Gonzalez Lopez Ledesma, Juan Pablo Zurano, Bianca Mazzitelli, Graciela Scruzzi, Paula Barbero, Diego Cardozo, Sandra Gallego, Mariel Borda, Miguel Diaz, Francisco Ridao, Angela Brigido Rosales, Jorge Bhon, Juan M. Talia, María E. Diangelo, María A. Lacaze, Balanzino Aime, Sebastian Isaac Gutierrez, Regina Ercole, Rosana Toro, Lorena Tau, Laura Delaplace, Malena Ferreyra Compagnucci, Celeste Sartori, Isabel Desimone, Cecilia Echegoyen, Pilar Velazquez, Clarisa Testa, Daniela Hozbor, Guillermo Docena, Carlos H. Laino, Nicolas Kreplak, Marina Pifano, Gabriela Barbas, Analía Rearte, Carla Vizzotti, Juan M. Castelli, Jorge Geffner, and Andrea V. Gamarnik

Subjects
SARS-CoV-2, Vaccination, COVID-19, Humans, Immunization, Viral Vaccines, RNA, Messenger, Antibodies, Viral, General Biochemistry, Genetics and Molecular Biology, 2019-nCoV Vaccine mRNA-1273
Abstract

Heterologous vaccination against coronavirus disease 2019 (COVID-19) provides a rational strategy to rapidly increase vaccination coverage in many regions of the world. Although data regarding messenger RNA (mRNA) and ChAdOx1 vaccine combinations are available, there is limited information about the combination of these platforms with other vaccines widely used in developing countries, such as BBIBP-CorV and Sputnik V. Here, we assess the immunogenicity and reactogenicity of 15 vaccine combinations in 1,314 participants. We evaluate immunoglobulin G (IgG) anti-spike response and virus neutralizing titers and observe that a number of heterologous vaccine combinations are equivalent or superior to homologous schemes. For all cohorts in this study, the highest antibody response is induced by mRNA-1273 as the second dose. No serious adverse events are detected in any of the schedules analyzed. Our observations provide rational support for the use of different vaccine combinations to achieve wide vaccine coverage in the shortest possible time.

Published
2022

5. Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape over Time

Author

Sebastian Gutierrez, Carla A. Pascuale, Guadalupe S. Costa Navarro, Natali B. Rasetto, Carolina Torres, Paul W. Rothlauf, Esteban Alberto Miglietta, Natalia Laufer, Claudia Varela, Valeria Ocho, Zhouming Liu, Pilar Velazquez, Diego E. Alvarez, Jorge Carradori, Laura Noelia Mojsiejczuk, Katherine Prost, Pamela E. Rodriguez, Gabriela Turk, Augusto Varesse, Diana Rosa Rodriguez Garcia, Cecilia Monzani, Marjorie Cornejo Pontelli, Andrea V. Gamarnik, Julio J. Caramelo, Regina Ercole, Horacio M. Pallarés, Ignacio Mazzitelli, Dolores Acuna, Louis Marie Bloyet, Marcelo J. Yanovsky, María José de Leone, Shirley D. Wenker, Martin Zubieta, Magalí G. Bialer, Maria Soledad Treffinger Cienfuegos, Yesica Longueira, Liloa Y. Ramis, Rasana I. Toro, María Mora González López Ledesma, Ana Ceballos, Mariana Viegas, Lautaro Sanchez, Santiago Oviedo Rouco, Jorge Geffner, Sean P. J. Whelan, C. Esteban Hernando, Andrés Hugo Rossi, Nicolás Kreplak, Alejandra Rima, Clarisa Testa, Luciana Bianchamino, Marina Pifano, Melina Salvatori, Mercedes Soledad Nabaes Jodar, Diego Sebastian Ojeda, and Antonella S. Rios

Subjects
Vaccination, biology, biology.protein, Alpha (ethology), Potency, Antibody, Beta (finance), Neutralizing antibody, Virology, Neutralization, Virus
Abstract

Recent studies have shown a temporal increase in the neutralizing antibody potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent individuals. Here, we examined longitudinal antibody responses and viral neutralizing capacity to the B.1 lineage virus (Wuhan related), to variants of concern (VOCs: Alpha, Beta, Gamma, and Delta) and a local variant of interest (VOI: Lambda) in volunteers receiving the Sputnik V vaccine in Argentina. A collection of 472 serum samples obtained between January and September 2021 was used. The analysis indicates that while anti-spike IgG levels significantly wane over time, the neutralizing capacity to the first-wave linages of SARS-CoV-2 and VOC are maintained within four months of vaccination. In addition, an improved antibody cross-neutralizing ability to circulating variants of concern (Beta, Gamma and Delta) was observed over time of vaccination. The viral variants that displayed higher escape to neutralizing antibodies with respect to the original virus (Beta and Gamma variants) were the ones showing the largest increase in susceptibility to neutralization over time after vaccination. Our observations indicate that serum neutralizing antibodies are maintained for at least four month and show a reduction of VOC escape over time of vaccination.

Published
2021
Full Text
View/download PDF

6. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose

Author

Dariana Pedrozza, Diego Sebastian Ojeda, Guadalupe S. Costa Navarro, Natali B. Rasetto, Diego E. Alvarez, Natalia Laufer, Santiago Sosa, Maria Soledad Treffinger Cienfuegos, Paula Gelpi, Antonella S. Rios, Magalí G. Bialer, María Mora González López Ledesma, Augusto Varese, Ignacio Mazzitelli, Lautaro Sanchez, Regina Ercole, Jorge Carradori, Guillermo Horacio Docena, Jorge Geffner, C. Esteban Hernando, Shirley D. Wenker, Santiago Oviedo Rouco, Andrea V. Gamarnik, Andrés Hugo Rossi, Alejandra Rima, Anabel Alvarez Juliá, Horacio M. Pallarés, Luciana Bianchimano, Marina Pifano, Susana Marchetti, Yesica Longueira, Nicolás Kreplak, Julio J. Caramelo, Marcelo J. Yanovsky, María José de Leone, Lila Y. Ramis, Martin Zubieta, Cecilia Echegoyen, and Corina I. García

Subjects
COVID-19 Vaccines, Health Personnel, COVIDAR IGG, Argentina, Antibodies, Viral, General Biochemistry, Genetics and Molecular Biology, Virus, NEUTRALIZING ANTIBODIES, Sputnik V, Report, Pandemic, Chlorocebus aethiops, SEROCONVERSION, Global health, Medicine, Animals, Humans, neutralizing antibodies, SARS-COV-2 VACCINATION, Seroconversion, Pandemics, Vero Cells, Vaccines, Vaccines, Synthetic, biology, business.industry, SARS-CoV-2, COVIDAR IgG, Vaccination, COVID-19, purl.org/becyt/ford/3.1 [https], Antibodies, Neutralizing, Titer, SARS-CoV-2 vaccination, HEK293 Cells, Cohort, Immunology, Spike Glycoprotein, Coronavirus, Ciencias Médicas, SPUTNIK V, biology.protein, WHO SARS-COV-2 ANTIBODY INTERNATIONAL STANDARD, purl.org/becyt/ford/3 [https], Antibody, business, WHO SARS-CoV-2 antibody International Standard
Abstract

Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, the limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies. We evaluate SARS-CoV-2-specific antibody responses after Sputnik V vaccination of healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses in a cohort of naive or previously infected volunteers. By 21 days after receiving the first dose of the vaccine, 94% of naive participants develop spike-specific IgG antibodies. A single Sputnik V dose elicits higher antibody levels and virus-neutralizing capacity in previously infected individuals than in naive ones receiving the full two-dose schedule. The high seroconversion rate after a single dose in naive participants suggests a benefit of delaying administration of the second dose to increase the number of people vaccinated. The data presented provide information for guiding public health decisions in light of the current global health emergency., Graphical abstract, Rossi et al. provide data on antibody responses to Sputnik V vaccine in naive and previously infected volunteers. This study shows a high seroconversion rate following the first dose in naive individuals. In seropositive participants, a single dose of Sputnik V elicits a fast and robust antibody response without apparent benefit from a second dose.

Published
2021

7. Surveillance of SARS-CoV-2 variants in Argentina: detection of Alpha, Gamma, Lambda, Epsilon and Zeta in locally transmitted and imported cases

Author

Ignacio Bourlot, Clara Theaux, Mariana Viegas, Carolina Cristina, Maria Colmeiro, Ailen Fernandez, Natalia Labarta, Sofia Di Bella, Manuel Arca, Laura Noelia Mojsiejczuk, Andrea Falaschi, Maria E Jofre, Stephanie Goya, María Florencia Eberhardt, Erica Luczak, Alejandro Castello, Marilina Rahhal, Franco Daniel Fernandez, Ariel Suarez, Dolores Acuna, Martin Zubieta, Andrés Ignacio Cordero, Jorgelina Suarez, Guido Alberto König, Monica Natale, Cecilia Camussone, Alejandra Musto, Andrea F. Puebla, Alicia Mistchenko, Silvina Lusso, Marcia Pozzati, Claudia Rechimont, Jonathan Zaiat, Andrea Gatelli, Belen Monaco, Rocio Larreche, Paula Sujanski, Gabriela Barbas, Regina Ercole, Sofia Alexay, Guillermo Thomas, Carla Medina, Marianne Munoz, Marcelo Mandile, Maria B Zaffanella, Estefania Tittarelli, Matias Irazoqui, Maria Elina Acevedo, Jose Jaramillo, Luciana Montoto, Ariel Fernando Amadio, Mercedes Soledad Nabaes Jodar, Melina Mazzeo, Yesica Espasandin, Viviana Leiva, Maria Laura Alvarez, Facundo Fernandez Moll, Maria A Lacaze, Sebastian Zunino, Osvaldo Cesar Uez, Leticia Siri, Carlos Espul, Darío Fernández Do Porto, Cecilia Ziehm, Cintia Streitenberger, Julieta Spina, Laura Valinotto, Sandra Goni, Humberto Julio Debat, Viviana Mugna, Marco Cacciahue, Gonzalo Castro, Agustina Bonnet, Maria Ines Gismondi, Cristina López, Sofia Bengoa, Carolina Ceriani, Viviana Ré, Luis Pianciola, María José Dus Santos, Paula C. Aulicino, Federico Remes Lenicov, Gustavo Levin, Andres Angelletti, Patricia Angeleri, Vanesa Seery, Carlos Cimino, Nathalie Marquez, Juan M Talia, Marina Ticeira, Rosana Toro, Gabriela Rompato, Ana Bertone, Belén Pisano, Guillermo Ojeda, Carla Massone, Ezequiel Sosa, Carolina Pintos, Carolina Torres, and Julian Cipelli

Subjects
Sanger sequencing, Limited access, symbols.namesake, Geography, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Capital city, symbols, Coding region, Lambda, Cartography, Rapid response
Abstract

Molecular surveillance of SARS-CoV-2 variants was performed on a total of 2,406 samples from the capital city and nine provinces of Argentina, during 30 epidemiological weeks (EW) that covered the end of the first wave and the beginning of the ongoing second wave of the COVID-19 pandemic in the country (EW 44/2020 to EW 20/2021). The surveillance strategy was mainly based on Sanger sequencing of a Spike coding region that allows the simultaneous identification of signature mutations associated with worldwide circulating variants. In addition, whole SARS-CoV-2 genome sequences were obtained from 456 samples. The main variants found were Gamma, Lambda and Alpha, and to a lesser extent, Zeta and Epsilon. Whereas Gamma dominated in different regions of the country, both Gamma and Lambda prevailed in the most populated area, the metropolitan region of Buenos Aires (MABA), although showing a heterogeneous distribution along this region. This cost-effective surveillance protocol allowed for a rapid response in a limited access to resources scenario, added information on the expansion of the Lambda variant in South America and contributed to the implementation of public health measures to control the disease spread in Argentina.

Published
2021
Full Text
View/download PDF

8. Surveillance of SARS-CoV-2 variants in Argentina: detection of Alpha, Gamma, Lambda, Epsilon and Zeta in locally transmitted and imported cases

Author

Carolina, Torres, primary, Laura, Mojsiejczuk, additional, Dolores, Acuña, additional, Sofía, Alexay, additional, Ariel, Amadio, additional, Paula, Aulicino, additional, Humberto, Debat, additional, Franco, Fernández, additional, Stephanie, Goya, additional, Guido, König, additional, Mercedes, Nabaes Jodar, additional, Luis, Pianciola, additional, Sofía, Bengoa, additional, Marco, Cacciahue, additional, Cecilia, Camussone, additional, José, Dus Santos María, additional, Florencia, Eberhardt María, additional, Ailen, Fernandez, additional, Inés, Gismondi María, additional, Matías, Irazoqui, additional, Silvina, Lusso, additional, Nathalie, Marquez, additional, Marianne, Muñoz, additional, Mónica, Natale, additional, Belén, Pisano, additional, Andrea, Puebla, additional, Viviana, Re, additional, Ezequiel, Sosa, additional, Jonathan, Zaiat, additional, Sebastián, Zunino, additional, Darío, Do porto, additional, Elina, Acevedo María, additional, Cristina, Alvarez Lopez, additional, Laura, Álvarez María, additional, Patricia, Angeleri, additional, Andrés, Angelletti, additional, Manuel, Arca, additional, Gabriela, Barbas, additional, Ana, Bertone, additional, Agustina, Bonnet, additional, Ignacio, Bourlot, additional, Alejandro, Castello, additional, Gonzalo, Castro, additional, Carolina, Ceriani, additional, Carlos, Cimino, additional, Julián, Cipelli, additional, María, Colmeiro, additional, Andrés, Cordero, additional, Carolina, Cristina, additional, Sofia, Di Bella, additional, Regina, Ercole, additional, Yesica, Espasandin, additional, Carlos, Espul, additional, Andrea, Falaschi, additional, Facundo, Fernandez Moll, additional, Andrea, Gatelli, additional, Sandra, Goñi, additional, Estela, Jofré María, additional, José, Jaramillo, additional, Natalia, Labarta, additional, Agustina, Lacaze María, additional, Rocio, Larreche, additional, Viviana, Leiva, additional, Gustavo, Levin, additional, Erica, Luczak, additional, Marcelo, Mandile, additional, Carla, Massone, additional, Melina, Mazzeo, additional, Carla, Medina, additional, Belén, Monaco, additional, Luciana, Montoto, additional, Viviana, Mugna, additional, Alejandra, Musto, additional, Guillermo, Ojeda, additional, Carolina, Pintos, additional, Marcia, Pozzati, additional, Marilina, Rahhal, additional, Claudia, Rechimont, additional, Federico, Remes Lenicov, additional, Gabriela, Rompato, additional, Vanesa, Seery, additional, Leticia, Siri, additional, Julieta, Spina, additional, Cintia, Streitenberger, additional, Ariel, Suárez, additional, Jorgelina, Suárez, additional, Paula, Sujanski, additional, Manuel, Talia Juan, additional, Clara, Theaux, additional, Guillermo, Thomas, additional, Marina, Ticeira, additional, Estefanía, Tittarelli, additional, Rosana, Toro, additional, Osvaldo, Uez, additional, Belén, Zaffanella María, additional, Cecilia, Ziehm, additional, Martin, Zubieta, additional, Alicia, Mistchenko, additional, Laura, Valinotto, additional, and Mariana, Viegas, additional

Published
2021
Full Text
View/download PDF

9. Persistencia de anticuerpos IgG contra SARS-CoV2 en personal de salud - provincia de Buenos Aires

Author

Nicolás Kreplak, Rosa Bologna, Laura Fischerman, Regina Ercole, Laura Muñoz, Yamila Comes, Marina Pifano, and Enio Garcia

Subjects
business.industry, Medicine, Seroepidemiologic Studies, business, Virology, Coronavirus Infections
Abstract

Objetivo: evaluar la persistencia de los anticuerpos IgG contra SARS-CoV2, en trabajadores de salud del subsector público de la Provincia de Buenos Aires, y correlacionarla con variables demográficas (sexo, edad) y otros indicadores de salud (diagnóstico de COVID-19, comorbilidades y embarazo). Metodología: Estudio descriptivo, observacional, de corte transversal. Al personal de salud con un resultado positivo en una primera muestra (N=388) se les realizó una segunda prueba para evaluar la persistencia de anticuerpos mediante ELISA. Resultados: De las 386 personas evaluadas con resultado concluyente, 296 contaban con un primer resultado positivo entre los 30 y los 90 días anteriores a la segunda prueba, el 90% presentó anticuerpos detectables. En aquellas personas con un resultado positivo hacía más de 90 días (45) se observó una caída significativa en la persistencia del 26,7%. No hubo asociaciones significativas entre las variables demográficas y de salud y el resultado de la segunda prueba. Conclusión: Los anticuerpos se mantienen detectables por al menos 90 días en el 90% de los casos analizados. Resulta fundamental continuar este estudio en el tiempo para contar con un período de tiempo mayor entre pruebas. La información aquí mostrada arroja datos interesantes y prometedores en cuanto a la posible protección de nuevos contagios de COVID-19 en personal con alta exposición de riesgo. Estas evidencias podrían contribuir a la toma de decisiones, tanto a nivel local como regional, para la adecuada planificación de la vacunación, así como también, para el manejo de la pandemia ante una posible segunda ola de casos en América Latina.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results